Neurocrine Biosciences, Inc.
12780 El Camino Real
San Diego, CA 92130
Phone: (858) 617-7600Website: https://www.neurocrine.com/Careers: www.neurocrine.com/applications...
- FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
27 April 2020
- Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
10 July 2019
- Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
14 February 2018
- Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
11 April 2017
- Neurocrine Provides Update on FDA Advisory Committee for Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
5 January 2017
- Neurocrine Announces FDA Advisory Committee Meeting to Review Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia
29 November 2016
- Neurocrine Announces Ingrezza (valbenazine) NDA for the Treatment of Tardive Dyskinesia has been Accepted for Priority Review by FDA
11 October 2016
- Neurocrine Announces FDA Conditional Acceptance of Proprietary Name Ingrezza for VMAT2 Inhibitor Valbenazine
31 August 2016
- Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia
29 August 2016
- Neurocrine Receives Approvable Letter for Indiplon Capsules with
Additional Safety and Efficacy Data Required by FDA
13 December 2007
Drugs Associated with Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: valbenazine
Drug class: VMAT2 inhibitors
|12 reviews||4.3 / 10|
Generic name: opicapone
Drug class: dopaminergic antiparkinsonism agents
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|